OrnidazoleThird Party Manufacturing in India

Ornidazole works by directly damaging the DNA of susceptible anaerobic bacteria and protozoa, leading to their death.

It enters the microbial cell via passive diffusion, where its nitro group is chemically reduced by the organism's intracellular enzymes to highly reactive short-lived intermediates. These intermediate compounds interact with microbial DNA, causing strand breakage and destabilization of the DNA helix. This structural destruction rapidly inhibits protein synthesis and causes cell death.

Unlike other nitroimidazoles like metronidazole, Ornidazole generally has a longer half-life, allowing for less frequent dosing and better patient compliance. It is highly effective for treating complex protozoal and mixed anaerobic infections.

Therapeutic Uses

Ornidazole is prescribed for the treatment of:

• Amoebiasis: Treats intestinal and extraintestinal infections caused by Entamoeba histolytica.
• Giardiasis: Eradicates Giardia lamblia infections causing severe diarrhea.
• Trichomoniasis: Treats urogenital infections in both male and female patients.
• Anaerobic Bacterial Infections: Used in surgical prophylaxis and treatment of deep-seated anaerobic bacterial infections.

Why Manufacturers Choose Ornidazole

Due to its broad-spectrum efficacy against common water-borne protozoa and anaerobic bacteria, Ornidazole is widely prescribed in developing markets. Its formulation stability and longer half-life give it a competitive edge over older alternatives in the market.

This makes Ornidazole a highly demanded molecule for third party manufacturing in India, frequently produced both as a standalone tablet and in combinations with fluoroquinolones.